

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>Gary V. Burton, MD</b>		POSITION TITLE Professor of Medicine Associate-Director of Clinical Research Director of Outpatient Oncology Units Director Breast and Brain Tumor programs	
eRA COMMONS USER NAME GBURTON			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Weber State College, Ogden, Utah	BS	1970-1974	Zoology
University of Utah College of Medicine, Salt Lake City, Utah	MD	1974-1978	Medicine
Resident in Medicine, Duke University Medical Center, Durham, NC		1978-1981	Internal Medicine
Fellow in Hematology/Oncology, Duke University Medical Center, Durham, NC		1981-1983	Hematology/Oncology

**A. Personal Statement**

I have been a faculty member at LSUHSC-Shreveport (LSUHSC-SH) since 1986 and have contributed to the development of an active clinical research program. I have been involved with the SWOG group since 1986 and NSABP since 1989. Most of my efforts have been directed toward adjuvant breast cancer trial participation in addition to being SWOG PI on brain tumor and sarcoma trials. I am currently the associate-director for Clinical Cancer Research at LSUHSC-Shreveport Feist-Weiller Cancer Center and SWOG PI for our institution since 2011 and a co-Investigator on the LSUHSC-SH NCI Minority-Based CCOP grant. My LSUHSC-SH clinical responsibilities include direction of the Multi-disciplinary Breast Cancer and Brain Tumor programs as well as coordination of all cancer center clinical trials. My research interests include adjuvant therapy of breast cancer, and management of primary brain tumors with interests in cancer control issues relative to breast cancer. I have extensive experience working with medically underserved populations and have developed culturally sensitive institutional programs that have improved patient understanding of clinical cancer trials with a resultant improvement in minority trial participation. I also have extensive experience providing direct patient care to these medically underserved populations. My GS-MB-NCORP responsibility will be as the leader of the Clinical Trials Program.

**B. Positions and Honors****Positions**

1983-1986 – Associate in Medicine, Duke University Medical Center, Durham, NC  
 1986-1987 – Assistant Professor of Medicine, Duke University Medical Center, Durham, NC  
 1987-1989 – Clinical Associate in Medicine, Duke University Medical Center, Durham, NC  
 1986-1991 – Assistant Professor of Medicine, LSUHSC-Shreveport, Shreveport, LA  
 1991-2000 – Associate Professor of Medicine, LSUHSC-Shreveport, Shreveport, LA  
 2000-present – Professor of Medicine, LSUHSC-Shreveport, Shreveport, LA

**Honors**

James A. Busch Memorial Research Award, University of Utah College of Medicine  
 Alpha Omega Alpha Honor Society  
 Alan Copping Teaching Award, 2001 - LSUHSC-Shreveport, Shreveport, LA  
 Humanism In Medicine Award, 2003 - LSUHSC-Shreveport, Shreveport, LA

**C. Selected peer-reviewed publications (in chronological order)**

1. Bowen CD, **Burton GV**, Bargaen RC, Madonia P, Zhang S, Toledo EG, Zweig R, Pant C. Carcinomatous meningitis secondary to transitional cell bladder cancer. South Med J 103:809-12, 2010.

2. Parker CC, Ampil F, **Burton G**, Li BD, Chu QD. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? *Surgery* 148:386-91, 2010.
3. Chu QD, **Burton G**, Glass J, Smith MH, Li BD. Impact of race and ethnicity on outcomes for estrogen receptor-negative breast cancers: experience of an academic center with a charity hospital. *J Am Coll Surg* 210:585- 594, 2010.
4. Koshy N, Quispe D, Shi R, Mansour R, **Burton GV**. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. *Breast* 19:246-8, 2010.
5. Pant C, Sferra TJ, Bass PF, **Burton GV**, Minocha A. Optimum timing of blood tests for monitoring patients with clostridium difficile-associated diarrhea. *J Investig Med* 58:621-624, 2010.
6. Li BD, Sicard MA, Ampil F, Abreo F, Lilien D, Chu QD, **Burton GV**. Trimodal Therapy for Inflammatory Breast Cancer: A Surgeon's Perspective. *Oncology* 79:3-12, 2010.
7. Quispe D, Shi R, **Burton G**. Osteonecrosis of the jaw in patients with metastatic breast cancer: Ethnic and socio-economic aspects. *Breast J* 17:510-513, 2011.
8. Chu Q, Henderson A, Kim R, Miller JK, **Burton G**, Ampil F, Li DL. Should a routine metastatic workup be performed for all patients with pathologic N2/N3 breast cancer. *J Am Coll Surg* 214, 456-462, 2012.
9. Ampil F, Caldito G, Henderson B, Li b, Kim RH, **Burton G**, Chu Q. Carcinoma of the axillary tail of Spence: A case series. *Anticancer Res* 32:4057-4060, 2012.
10. Ampil FL, Li BD, **Burton GV**, Kim RH, Baluna RG, Chu Q. Is Baseline Bone Imaging in High-Risk Breast Cancer Patients Justified? *Breast J*. 2012 Sep 26. doi: 10.1111/tbj.12021.
11. Watson KS, Mills GM, **Burton GV**. Superwarfarin intoxication: two case reports and review of pathophysiology and patient management. *J La State Med Soc* 164:70-2, 2012.
12. Escobar C, Munker R, Thomas JO, Li BD, **Burton GV**. Update on desmoid tumors. *Ann Oncol* 23:562-9, 2012.
13. Mowad R, Chu QD, Li BD, **Burton GV**, Ampil FL, Kim RH. Does obesity have an effect on outcomes in triple-negative breast cancer? *J Surg Res* 2013 June 2. doi:pil: S0022-4804(13)00487-3. 10.1016/j.jss.2013.05.037.
14. Shi R, Mills G, McLarty J, **Burton G**, Shi Z, Glass J. Commercial insurance triples chances of breast cancer survival in a public hospital. *Breast J*. 2013 Nov;19(6):664-7.
15. Ampil F, Caldito G, Li B, Devarakonda S, **Burton G**, Kim RH, Chu Q. Morbid obesity does not disadvantage patients with in situ or early-stage carcinoma undergoing breast-conserving surgery. *Anticancer Res*. 2013 Sep;33(9):3867-9.

## D. Research Support

### Current Research Support

**U10CA128567**

08/01/2007-05/31/2015

NIH-NCI

LSUHSC-Shreveport Feist Weiller Cancer Center MBCCOP

The Feist-Weiller Cancer Center (FWCC) Minority-Based Community Clinical Oncology Program (MB-CCOP) aims to provide increased access to state-of-the-art cancer prevention care, and control through NCI-sponsored clinical trials to the minority and indigent populations in the northwestern section of La., and throughout the state of Louisiana.

Role: Co-investigator

**Celldex Therapeutics, Inc.**

09/05/12 – Present

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

**EMD Serono**

08/19/13 – Present

A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination with TH-302 Compared with Gemcitabine in Combination with Placebo in Previously Untreated Subjects with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

**Research Support Completed Within 5 Years**

**Ziopharm Oncology**

10/6/2010 – 05/08/2013

A Phase III Multicenter, International, Randomized, Double-Blind, Placebo-Controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients with Front-Line Metastatic Soft Tissue Sarcoma

**Merrimack Pharmaceuticals**

03/02/2011 - 10/12/2012

A Randomized, Double-Blind Phase 2 Trial of Exemestane +/- MM-121 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+), Her2 negative Breast Cancer

**Pfizer**

03/06/2007 – 09/06/2011

A Randomized, Phase 3 Study of Sunitinib in Combination with Capecitabine Compared with Capecitabine in Patients with Previously Treated Breast Cancer

**BiPar Sciences**

11/04/2009 - 11/15/2011

A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, with or without BSI-201, in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer

**AstraZeneca Pharmaceuticals**

02/24/1997 – 04/27/2010

A Randomized, Double-Blind Trial Comparing ARIMIDEX® Alone with Nolvadex Alone with Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Postmenopausal Women with Breast Cancer

**AstraZeneca Pharmaceuticals**

10/15/2008 – 09/17/2009

A Phase III, Randomized, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib with Lomustine to the Efficacy of Lomustine alone

**Pfizer**

10/30/2006 – 09/08/2008

A Randomized Phase 2 Study of SU011248 Versus Standard-of-Care for Patients with Previously Untreated, Advanced, Triple Receptor Negative (ER, PR, and HER2) Breast Cancer

**Pfizer**

01/29/2007 – 10/29/2008

A Randomized, Phase 3 Study of Docetaxel in Combination with Sunitinib Versus Docetaxel in the First-Line Treatment of Advanced Breast Cancer Patients